Skip to content

Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain

Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00917436
Enrollment
183
Registered
2009-06-10
Start date
2004-12-31
Completion date
2005-07-31
Last updated
2010-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Brief summary

To assess two regimens of thiocolchicoside injection and capsule in combination with either diclofenac or ibuprofen in patients with acute low back pain.

Interventions

Sponsors

Sanofi
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of acute low back pain of recent onset (less than 7 days) and defined by spontaneous pain intensity at rest more than or equal to 50mm of the visual analog scale. * Presence of lumbar muscular contracture

Exclusion criteria

* Acute low back pain due to vertebral collapse or neoplastic, inflammatory (ankylosing spondylitis), or infective origins * Patients with psychiatric or mental diseases, or unable to follow the requests of the protocol * Renal failure (serum creatinine \> 160 µmol/l or \> 1.80 mg/dl) and/or severe hepatic dysfunction (alanine aminotransferase and/or aspartate aminotransferase and/or total bilirubin \> 2 Upper normal limit). * Positive history of cerebro-vascular accidents or myocardial infarction in the six months prior the inclusion. * Severe heart failure. * Myopathy / myasthenia. * Patients treated during two days prior to inclusion with steroidal agents. * Known or suspected hypersensitivity to thiocolchicoside. * Known or suspected hypersensitivity to nonsteroidal anti-inflammatory drugs * History of active peptic ulcer or gastro intestinal bleeding. * History of nonsteroidal anti-inflammatory drugs induced allergic asthma. * Concomitant treatment with 2-agonists (i.e. clonidine). * Pregnant or breast feeding women. * Females of child bearing potential, not taking adequate contraception. * Patients with history of alcohol, drugs or narcotics abuse. * Previous inclusion in this study or in another study in the past 6 months.

Design outcomes

Primary

MeasureTime frame
Pain score evaluated by patient-rated visual analog scale: the levels of spontaneous pain is indicated by the patient by means of a 10 centimetre non-graduated scale, in which the patient could estimate the intensity of painDuring patient visits: day 1, day 3 and day 5 to 10

Secondary

MeasureTime frame
Mobility Hand-to-floor distance is evaluated by a simple graduated bar (0 value at floor).During patient visits: day 1, day 3 and day 5 to 10
Disability Questionnaire (Roland Morris)During patient visits: day 1, day 3 and day 5 to 10
Physician rated Clinical Global Impression ScaleDuring patient visits: day 1, day 3 and day 5 to 10

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026